DP-R208 Pharmacokinetic Study

DP-R208 Pharmacokinetic Study Phase I

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R208 (Candesartan cilexetil 8mg/Rosuvastatin 10mg), a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers

Inclusion Criteria:

• BMI 18~30
• signed the informed consent form prior to the study participation

Exclusion Criteria:

• Clinically significant disease
• Previously donate whole blood within 60 days or component blood within 14 days
• Clinically significant allergic disease
• Taken IP in other trial within 90 days
• An impossible one who participates in clinical trial by investigator's decision including laboratory test result